GSK/Theravance Target 2008 Phase III Start For Next-Gen Bronchodilators
This article was originally published in The Pink Sheet Daily
Executive Summary
Two compounds stemming from the collaboration given once daily were equivalent to salmeterol twice daily in Phase IIb clinical studies.
You may also be interested in...
Theravance Trims Loss, CEO “Optimistic” About FDA Panel Ahead
Feb. 27 brings first test of noninferiority’s importance to regulators, analyst tells “The Pink Sheet” DAILY.
Theravance Trims Loss, CEO “Optimistic” About FDA Panel Ahead
Feb. 27 brings first test of noninferiority’s importance to regulators, analyst tells “The Pink Sheet” DAILY.
Dey Perforomist Inhalation Solution Clears FDA for Bronchoconstriction In COPD
Approval marks the first FDA-approved nebulizer formulation of formoterol.